Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Clay

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
BMC Immunology|March 28, 2008
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker, Jeffrey Hassler, Janice K Payne, et al.
Cancer Investigation|August 7, 2003
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNAMichael A Morse, Smita K Nair, Paul J Mosca, et al.
Breast Cancer Research : BCR|June 9, 2012
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cellsXiu-Rong Ren, Junping Wei, Gangjun Lei, et al.
International Journal of Cancer|October 27, 2009
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse, Junping Wei, Zachary Hartman, et al.
BMC Immunology|July 20, 2005
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOTHolden T Maecker, James Moon, Sonny Bhatia, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman, Junping Wei, Takuya Osada, et al.
Current Problems in Surgery|January 30, 2004
Immunotherapy of surgical malignanciesMichael A Morse, H Kim Lyerly, Timothy M Clay, et al.
Plos One|October 11, 2012
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model systemNicholas C D'Amato, Julie H Ostrander, Michelle L Bowie, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsMichael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
BMC Immunology|March 28, 2008
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptidesHolden T Maecker, Jeffrey Hassler, Janice K Payne, et al.
Cancer Investigation|August 7, 2003
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNAMichael A Morse, Smita K Nair, Paul J Mosca, et al.
Breast Cancer Research : BCR|June 9, 2012
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cellsXiu-Rong Ren, Junping Wei, Gangjun Lei, et al.
International Journal of Cancer|October 27, 2009
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse, Junping Wei, Zachary Hartman, et al.
BMC Immunology|July 20, 2005
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOTHolden T Maecker, James Moon, Sonny Bhatia, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman, Junping Wei, Takuya Osada, et al.
Current Problems in Surgery|January 30, 2004
Immunotherapy of surgical malignanciesMichael A Morse, H Kim Lyerly, Timothy M Clay, et al.
Plos One|October 11, 2012
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model systemNicholas C D'Amato, Julie H Ostrander, Michelle L Bowie, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsMichael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, et al.
Pageof 8